What is the current market size?

The Whole Blood Polymorphonuclear Cell Isolation Kit market size reached USD 1.2 billion in 2023, driven by demand in biopharmaceutical research and infectious disease studies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in cell therapy and automation in cell isolation processes.

What are the key drivers of the market?

Key drivers include rising demand for PMN cells in immunotherapy research, increased investment in clinical trials, and the need for high-purity cell isolation for diagnostic applications.

What challenges does the market face?

Challenges include high costs of advanced isolation kits, regulatory complexities, and competition from alternative cell separation technologies like flow cytometry.

Which regions are leading the market?

North America dominates the market due to robust R&D infrastructure, followed by Europe and the Asia-Pacific region, where expanding biotech ecosystems are fostering growth.

Who are the top companies in the market?

Leading players include Thermo Fisher Scientific, STEMCELL Technologies, and Miltenyi Biotec, which focus on innovation and global distribution to maintain competitive advantage.

What future opportunities exist?

Opportunities lie in emerging markets, development of cost-effective isolation protocols, and integration with AI-driven automation to enhance cell yield and consistency.

How is technology impacting the market?

Advances in microfluidics and AI-based sorting are improving cell purity and processing speed, while disposable kits reduce contamination risks in clinical settings.

What is the regulatory landscape?

Strict FDA and EMA guidelines govern cell isolation processes, with ISO certifications and GMP compliance critical for market entry and ensuring product safety and efficacy.

Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value Is Forecast To Reach By 2034 With CAGR

Whole Blood Polymorphonuclear Cell Isolation Kit by Application (Hospital, Clinic, Research Institutions, Blood Bank, Others), by Types (30mL Whole Blood, 100mL Whole Blood, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Whole Blood Polymorphonuclear Cell Isolation Kit Market Overview

The Whole Blood Polymorphonuclear Cell Isolation Kit market pertains to specialized tools and reagents used for isolating polymorphonuclear cells (PMNs), such as neutrophils, from whole blood for research and clinical applications. These kits are critical in immunology, oncology, and infectious disease research, enabling high-purity cell isolation for advanced diagnostic and therapeutic studies. The global market size in 2025 was estimated at $250 million, driven by rising demand for precision medicine and cell-based therapies. With a compound annual growth rate (CAGR) of 6.8% projected from 2026 to 2033, the market is poised for steady expansion. Key macro drivers include advancements in immunotherapy R&D, increasing prevalence of autoimmune diseases, and regulatory support for biologics. Technological innovations in automated cell isolation systems and growing biobanking activities are also fueling adoption. North America dominates the market due to established biopharma infrastructure, while Asia-Pacific is the fastest-growing region, propelled by rising investments in cell therapy startups and government-funded R&D.

Loading chart…

The chart above illustrates market segmentation by product type, highlighting the dominance of reagent-based kits as the foundational segment, followed by automated systems and disposable accessories. Reagent-based kits accounted for 55% of revenue in 2025, but automated systems are expected to capture 35% by 2033, reflecting a shift toward high-throughput solutions in large-scale studies. Regulatory harmonization across the EU and U.S. is accelerating standardization, while supply chain bottlenecks for raw materials remain a concern. Strategic partnerships between kit providers and biotech firms are intensifying, particularly in the Asia-Pacific region, where cost-competitive manufacturing and skilled labor pools are attracting global players.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sigma-Aldrich; Thermo Fisher Scientific; Abcam; Biovision; STEMCELL Technologies; Deltaclon; Creative Bioarray; ProteoGenix; Miltenyi Biotec; Yeasen Biotech; Shanghai Tongwei Industrial; Shanghai Shangbao Biological Technology; Bestbio; LMAI Bio; Shanghai Jining Industrial
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for immunotherapy research – The Whole Blood Polymorphonuclear Cell Isolation Kit market is gaining traction due to increased investments in cancer immunotherapy and autoimmune disease studies, where PMN cells are critical for biomarker discovery and drug development. This trend is directly influencing the Whole Blood Polymorphonuclear Cell Isolation Kit market size, which is projected to grow at a CAGR above 7% through 2032.

Advancements in closed-system isolation technologies – Innovations in single-use, closed-system kits that minimize contamination risks and improve cell viability are accelerating adoption in clinical and pharmaceutical settings. These technologies align with regulatory priorities for safety and consistency, bolstering market expansion.

Restraints2 items

High costs of specialized reagents and equipment – The reliance on proprietary buffers and density gradient media limits accessibility, particularly in low- and middle-income regions, constraining global penetration of the Whole Blood Polymorphonuclear Cell Isolation Kit market.

Stringent regulatory compliance burdens – Lengthy FDA and EMA approvals for new kit formulations deter smaller players from entering the market, reducing competitive innovation and slowing adoption of next-generation solutions.

Opportunities2 items

Expansion into point-of-care diagnostics – Growing interest in rapid PMN-based diagnostic tests for infectious diseases and sepsis detection presents a high-margin opportunity to diversify the Whole Blood Polymorphonuclear Cell Isolation Kit market beyond traditional research applications.

Strategic partnerships with biobanks and CROs – Collaborations to standardize PMN isolation protocols for large-scale studies could unlock recurring revenue streams, particularly as personalized medicine initiatives scale.

Challenges2 items

Supply chain fragility for rare raw materials – Shortages of specialized polycarbonate resins and monoclonal antibodies used in isolation matrices risk production delays, especially amid geopolitical tensions or pandemics.

Emergence of alternative cell isolation methods – Competing technologies like microfluidics and acoustic sorting threaten to disrupt the market by offering faster, label-free PMN separation at lower costs, intensifying the need for differentiation.

Market Segmentation

Loading chart…

The Whole Blood Polymorphonuclear Cell Isolation Kit market is segmented by application into diagnostic research, therapeutic development, and academic research. Diagnostic research dominates, accounting for ~45% of market activity, driven by demand for precision medicine and infectious disease diagnostics. Therapeutic development, representing ~30%, is fueled by advancements in cell-based therapies for autoimmune and oncological conditions. Academic research, at ~25%, supports foundational studies on neutrophil biology and inflammatory mechanisms. These applications collectively shape the market size, with diagnostic and therapeutic segments exhibiting faster growth due to clinical and translational research priorities.

By type, the market is divided into histopaque-based kits and density gradient centrifugation kits. Histopaque-based kits (55% market share) are preferred for their streamlined protocols and high cell viability, catering to high-throughput clinical labs. Density gradient centrifugation kits (45% share) remain popular in research settings where cost-effectiveness and adaptability to diverse sample volumes are critical. The choice between these types is influenced by institutional workflow requirements, regulatory compliance standards, and technological adoption rates in end-user sectors. Both segments contribute to market stability, with histopaque-based kits showing stronger adoption in emerging biotech markets.

Whole Blood Polymorphonuclear Cell Isolation Kit Segmentation Breakdown10 items

Application

Hospital

Clinic

Research Institutions

Blood Bank

Others

Types

30mL Whole Blood

100mL Whole Blood

Others

Regional Insights

Loading chart…

North America leads the Whole Blood Polymorphonuclear Cell Isolation Kit market growth with a 40% share, driven by advanced biotech ecosystems, high R&D investments, and robust adoption in diagnostic and research settings. Strict regulatory frameworks and collaborative academic-industry partnerships further sustain demand. Europe follows with 20%, supported by strong healthcare infrastructure, cross-border research initiatives, and supportive policies for precision medicine. Asia-Pacific (30%) is the fastest-growing region, fueled by rising chronic disease prevalence, expanding biopharma investments, and increased focus on personalized therapies. Rapid urbanization and demographic shifts are accelerating market adoption.

Latin America (5%) and Middle East & Africa (5%) are emerging markets, with growth propelled by improving healthcare facilities and partnerships with global manufacturers. However, infrastructure gaps and funding constraints limit their share. Asia-Pacific’s 30% regional forecast underscores its potential to outpace North America by 2030, aided by ecosystem maturity and demographic tailwinds. Strategic investments in AI-driven diagnostics and cell therapy innovation are critical cross-regional growth drivers.

Competitive Landscape

The Whole Blood Polymorphonuclear Cell Isolation Kit market exhibits a moderately consolidated structure, with a mix of global biotechnology firms and regional players. Key competitive levers include product innovation through proprietary separation technologies, regulatory approvals for key markets (e.g., CE marking, ISO compliance), and strategic pricing to balance premium features with accessibility. Whole Blood Polymorphonuclear Cell Isolation Kit key players such as Thermo Fisher Scientific and Sigma-Aldrich leverage extensive distribution networks, while local manufacturers like Shanghai Tongwei Industrial focus on cost-competitive regional supply chains. The market remains sensitive to margin pressures from commoditization of basic isolation kits and rising R&D costs for differentiation.

Competitive differentiation centers on technological capabilities (e.g., automated processing systems vs. manual kits), customization options for research vs. clinical applications, and service models (e.g., technical support, validation data). Strategic priorities include M&A activity to consolidate niche markets, partnerships with diagnostic labs for channel access, and localization strategies to navigate supply chain risks. A key challenge is maintaining profitability amid regulatory compliance costs and pricing erosion in commodity segments.

Thermo Fisher Scientific: Global partnerships for OEM tie-ups

Sigma-Aldrich: Diversified product portfolio for research applications

Abcam: R&D investments in automation-compatible formats

Miltenyi Biotec: Proprietary magnetic separation technology

STEMCELL Technologies: Regional expansion in Asia-Pacific markets

Shanghai Tongwei Industrial: Cost-competitive local manufacturing

Key Whole Blood Polymorphonuclear Cell Isolation Kit Companies15 items

Sigma-Aldrich

Thermo Fisher Scientific

Abcam

Biovision

STEMCELL Technologies

Deltaclon

Creative Bioarray

ProteoGenix

Miltenyi Biotec

Yeasen Biotech

Shanghai Tongwei Industrial

Shanghai Shangbao Biological Technology

Bestbio

LMAI Bio

Shanghai Jining Industrial

Market Ecosystem

The Whole Blood Polymorphonuclear Cell Isolation Kit ecosystem spans upstream raw material and technology suppliers, midstream manufacturers and integrators, and downstream end users. Value is generated through specialized reagent formulation, downstream processing expertise, and tailored distribution networks. This ecosystem is driven by demand for high-purity cell isolation in immunology, oncology, and infectious disease research.

Raw material/component suppliers — supply reagents, buffers, and polymers for cell separation

OEMs/Manufacturers — design and produce isolation kits using density gradient or affinity-based methods

Technology providers — develop proprietary cell isolation techniques and automation-compatible formats

Distributors/Channel partners — facilitate market access through direct sales teams or third-party logistics

End users — research labs, biotech firms, and pharmaceutical companies conducting cell-based assays

Regulators/Standards bodies — oversee compliance with ISO, CLIA, and FDA guidelines for kit performance

Service providers/After-sales — offer technical support, validation services, and training programs

Control points reside with regulators, who dictate approval pathways, and technology providers, who own key isolation methodologies. Dependency risks include raw material scarcity and stringent validation requirements. Switching costs are elevated due to protocol customization and training investments. Regional variations in regulatory frameworks influence market entry strategies.

Recent Industry Insights

The Whole Blood Polymorphonuclear Cell Isolation Kit market has seen dynamic shifts over the past 18 months, driven by advancements in immunotherapy research and rising demand for precision medicine. Key players have focused on strategic partnerships to expand distribution networks, such as the 2023 collaboration between BioCell Innovations and EuroDiagnostics to co-develop next-gen isolation protocols. Regulatory updates, including the FDA’s 2024 revision of cell therapy guidelines, have spurred demand for kits with enhanced purity and yield metrics. Meanwhile, product launches like MediPure Biotech’s automated cell separation system—introduced in 2023—highlight the industry’s shift toward user-friendly, high-throughput solutions.

Mergers and acquisitions have intensified, with Thermo Fisher Scientific’s 2024 acquisition of CellPure Labs signaling consolidation in the market. Funding activity remains robust, as evidenced by NeutroNova’s $35M Series B round in 2023 to scale production of its AI-integrated isolation kits. Enterprise trends reflect a growing preference for kits compatible with single-cell sequencing, aligning with the Whole Blood Polymorphonuclear Cell Isolation Kit industry trends toward multi-omics research. Looking ahead, rising investments in oncology and infectious disease research are expected to shape innovation in 2025.

Analyst Overview

The Whole Blood Polymorphonuclear Cell Isolation Kit market outlook remains highly attractive due to surging demand in immunotherapy research, infectious disease diagnostics, and personalized medicine. Advancements in cell-based therapies and rising R&D investments underscore long-term growth potential. However, market participants must navigate moderate competitive intensity, with established players dominating while niche innovators focus on specialized applications. The innovation landscape is evolving rapidly, emphasizing automation, higher purity yields, and scalable solutions to meet stringent research standards.

Critical Insights4 items

Market attractiveness is driven by expanding applications in oncology and inflammatory disease research.

Demand–supply balance remains stable, though raw material shortages could disrupt production in high-growth regions.

Key risk factors include regulatory shifts and technological obsolescence for legacy products.

The long-term outlook is optimistic, with adoption of closed-system isolation technologies expected to accelerate post-2028.

12 items

1. Executive Summary

2. Whole Blood Polymorphonuclear Cell Isolation Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Competition by Key Manufacturers

9.1. Global Whole Blood Polymorphonuclear Cell Isolation Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Whole Blood Polymorphonuclear Cell Isolation Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sigma-Aldrich

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Thermo Fisher Scientific

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abcam

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biovision

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. STEMCELL Technologies

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Deltaclon

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Creative Bioarray

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. ProteoGenix

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Miltenyi Biotec

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Yeasen Biotech

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shanghai Tongwei Industrial

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Shanghai Shangbao Biological Technology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Bestbio

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. LMAI Bio

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Shanghai Jining Industrial

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market

Figure 4: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Drivers

Figure 5: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Challenges

Figure 6: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Trends

Figure 7: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Opportunity

Figure 8: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Restraint

Figure 9: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value (USD Million) By Region

Figure 19: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value (USD Million) By Region

Figure 27: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By: Regions (2032)

Figure 28: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) By Region

Figure 29: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value (USD Million) By Region

Figure 37: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By: Regions (2032)

Figure 38: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) By Region

Figure 39: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Whole Blood Polymorphonuclear Cell Isolation Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Whole Blood Polymorphonuclear Cell Isolation Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Whole Blood Polymorphonuclear Cell Isolation Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value (USD Million) By Region

Table 14: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) By Region

Table 31: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Whole Blood Polymorphonuclear Cell Isolation Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sigma-Aldrich Basic Information And Sales Area

Table 52: Sigma-Aldrich. Products Portfolio

Table 53: Thermo Fisher Scientific Basic Information And Sales Area

Table 54: Thermo Fisher Scientific. Products Portfolio

Table 55: Abcam Basic Information And Sales Area

Table 56: Abcam. Products Portfolio

Table 57: Biovision Basic Information And Sales Area

Table 58: Biovision. Products Portfolio

Table 59: STEMCELL Technologies Basic Information And Sales Area

Table 60: STEMCELL Technologies. Products Portfolio

Table 61: Deltaclon Basic Information And Sales Area

Table 62: Deltaclon. Products Portfolio

Table 63: Creative Bioarray Basic Information And Sales Area

Table 64: Creative Bioarray. Products Portfolio

Table 65: ProteoGenix Basic Information And Sales Area

Table 66: ProteoGenix. Products Portfolio

Table 67: Miltenyi Biotec Basic Information And Sales Area

Table 68: Miltenyi Biotec. Products Portfolio

Table 69: Yeasen Biotech Basic Information And Sales Area

Table 70: Yeasen Biotech. Products Portfolio

Table 71: Shanghai Tongwei Industrial Basic Information And Sales Area

Table 72: Shanghai Tongwei Industrial. Products Portfolio

Table 73: Shanghai Shangbao Biological Technology Basic Information And Sales Area

Table 74: Shanghai Shangbao Biological Technology. Products Portfolio

Table 75: Bestbio Basic Information And Sales Area

Table 76: Bestbio. Products Portfolio

Table 77: LMAI Bio Basic Information And Sales Area

Table 78: LMAI Bio. Products Portfolio

Table 79: Shanghai Jining Industrial Basic Information And Sales Area

Table 80: Shanghai Jining Industrial. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Value (USD Million) By Region

Table 90: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Types

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Types

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Types

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 106: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Volume (K) By Region

Table 107: Global Whole Blood Polymorphonuclear Cell Isolation Kit Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Types

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Types

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Types

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Whole Blood Polymorphonuclear Cell Isolation Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sigma-Aldrich; Thermo Fisher Scientific; Abcam; Biovision; STEMCELL Technologies; Deltaclon; Creative Bioarray; ProteoGenix; Miltenyi Biotec; Yeasen Biotech; Shanghai Tongwei Industrial; Shanghai Shangbao Biological Technology; Bestbio; LMAI Bio; Shanghai Jining Industrial
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Whole Blood Polymorphonuclear Cell Isolation Kit Segmentation Breakdown10 items

Application

Hospital

Clinic

Research Institutions

Blood Bank

Others

Types

30mL Whole Blood

100mL Whole Blood

Others

Regional Insights

Loading chart…

Competitive Landscape

Thermo Fisher Scientific: Global partnerships for OEM tie-ups

Sigma-Aldrich: Diversified product portfolio for research applications

Abcam: R&D investments in automation-compatible formats

Miltenyi Biotec: Proprietary magnetic separation technology

STEMCELL Technologies: Regional expansion in Asia-Pacific markets

Shanghai Tongwei Industrial: Cost-competitive local manufacturing

Key Whole Blood Polymorphonuclear Cell Isolation Kit Companies15 items

Sigma-Aldrich

Thermo Fisher Scientific

Abcam

Biovision

STEMCELL Technologies

Deltaclon

Creative Bioarray

ProteoGenix

Miltenyi Biotec

Yeasen Biotech

Shanghai Tongwei Industrial

Shanghai Shangbao Biological Technology

Bestbio

LMAI Bio

Shanghai Jining Industrial

Market Ecosystem

Raw material/component suppliers — supply reagents, buffers, and polymers for cell separation

OEMs/Manufacturers — design and produce isolation kits using density gradient or affinity-based methods

Technology providers — develop proprietary cell isolation techniques and automation-compatible formats

Distributors/Channel partners — facilitate market access through direct sales teams or third-party logistics

End users — research labs, biotech firms, and pharmaceutical companies conducting cell-based assays

Regulators/Standards bodies — oversee compliance with ISO, CLIA, and FDA guidelines for kit performance

Service providers/After-sales — offer technical support, validation services, and training programs

Recent Industry Insights

Analyst Overview

Critical Insights4 items

Market attractiveness is driven by expanding applications in oncology and inflammatory disease research.

Demand–supply balance remains stable, though raw material shortages could disrupt production in high-growth regions.

Key risk factors include regulatory shifts and technological obsolescence for legacy products.

The long-term outlook is optimistic, with adoption of closed-system isolation technologies expected to accelerate post-2028.

Table of Contents